PNB

PNB Vesper Life Sciences is a clinical-stage biopharmaceutical company based in India, focused on developing novel small molecule therapeutics for inflammatory diseases, oncology, and pain management. The company's lead candidate, PNB-001, is a highly potent cholecystokinin (CCK) receptor antagonist that has been evaluated in clinical trials for COVID-19-related lung inflammation and acute respiratory distress syndrome (ARDS). Beyond respiratory distress, PNB Vesper is advancing a pipeline targeting glioblastoma, chronic pain, and irritable bowel syndrome. The company leverages its expertise in medicinal chemistry and receptor pharmacology to address unmet medical needs. PNB Vesper maintains collaborations with international academic institutions to support its drug discovery and development efforts.